Home / Cannabis  / MedReleaf Corp gets $14 Buy Target from GMP

MedReleaf Corp gets $14 Buy Target from GMP

— James West

MedReleaf Corp (TSE:LEAF) (OTCMKTS:MEDFF) -whose shares have struggled to regain their IPO price of $9.50 a share since listing on the TSX June 15th – got a boost from GMP’s equities research group who today suggested a buy target of $14 per share.

“With two quarters of cash production costs hovering around $1.55 per gram, the company is solidifying its leading position as a low cost producer,” the research report said. “In addition, MedReleaf’s ability to mitigate the impact from the VAC’s price reimbursement cap is impressive considering the average price per gram decreased ~15% QoQ while company-wide revenues stayed stable.

The research team of Martin Landry, Andrew Partheniou, and Robert Fagan, went on to cite increased unit sales of cannabis and lower production costs of $1.53 reported in the company’s Q4 2017 financial results yesterday.

James West

James West

Editor and Publisher

I employ a Capital Efficiency Model that dictates money should never be exposed for longer than is absolutely necessary to the possibility of being lost. Thus, I routinely sell half my position when a stock doubles from my entry price, and I sell stocks that lose 20%, unless there are...
More Info...

midasletter@midasletter.com | |

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

NO COMMENTS

POST A COMMENT

Sign up for our free newsletter

and get more of MidasLetter delivered to your inbox.

Receive With your NEW subscription

Free and immediate access to these three recently published special reports